Order Article Reprints

Sinha A, Zou Y, Patel AS, Yoo S, Jiang F, Sato T, Kong R, Watanabe H, Zhu J, Massion PP, et al. Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Cancers. 2022; 14(3):708. https://doi.org/10.3390/cancers14030708

Sinha, Abhilasha, Yong Zou, Ayushi S. Patel, Seungyeul Yoo, Feng Jiang, Takashi Sato, Ranran Kong, Hideo Watanabe, Jun Zhu, Pierre P. Massion, and et al. 2022. "Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy" Cancers 14, no. 3: 708. https://doi.org/10.3390/cancers14030708

Sinha, A., Zou, Y., Patel, A. S., Yoo, S., Jiang, F., Sato, T., Kong, R., Watanabe, H., Zhu, J., Massion, P. P., Borczuk, A. C., & Powell, C. A. (2022). Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Cancers, 14(3), 708. https://doi.org/10.3390/cancers14030708